



ASX & Media Release

Rights Issue Closes Oversubscribed

Melbourne, Australia; February 14, 2018: Patrys Limited (**ASX: PAB**), a therapeutic antibody development company, is pleased to announce that the fully underwritten non-renounceable 2:11 Rights Issue at 1.7 cents raising approximately \$2.4 million before costs, as announced on 15 January 2018 has closed oversubscribed by over 45%.

In accordance with the terms of the Offer, the Company has exercised its discretion and scaled back applications for shares under the top up facility that was made available as part of the Offer.

The Company will scale back applications under the top up facility having regard to the applicant's Entitlement.

Refunds for the unallocated portion of the applications for additional shares under the top up facility will be refunded following the scale back. It is expected that the new shares will be issued and allotted on Friday 16 February 2018, with holding statements to be despatched on or about 20 February 2018.

Shareholders are advised to confirm their shareholding before trading in the Company's securities.

The Board would like to thank all shareholders for their continued support of the Company, and in addition would like to thank the Underwriter, Somers and Partners Pty Limited for their role in the Rights Issue.

-Ends-

For further information, please contact:

Patrys Limited:
James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.